Cardiff Oncology, Inc. (CRDF)
Stock Price:
$6.46 USD
0.35 (5.73%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
128.99M |
| Revenue (ttm) |
250,315 |
| Net Income (ttm) |
-16.60M |
| Shares Out |
19.97M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$6.46 |
| Previous Close |
$6.11 |
| Change ($) |
0.35 |
| Change (%) |
5.73% |
| Day's Open |
6.20 |
| Day's Range |
6.20 - 6.71 |
| Day's Volume |
834,896 |
| 52-Week Range |
0.70 - 6.85 |
More Stats
| Market Cap |
128.99M |
| Enterprise Value |
121.24M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.97M |
| Float |
9.73M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
545,359 |
| Short Ratio |
1.12 |
| Short % of Float |
5.00% |
| Beta |
1.46 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
515.33 |
| PB Ratio |
18.49 |
| Revenue |
250,315 |
| Operating Income |
-16.84M |
| Net Income |
-16.60M |
| Free Cash Flow |
-13.34M |
| Net Cash |
7.76M |
| Net Cash / Share |
0.39 |
| Gross Margin |
-4,361.55% |
| Operating Margin |
-6,727.03% |
| Profit Margin |
-4,745.80% |
| FCF Margin |
-5,331.06% |
| ROA |
-79.89% |
| ROE |
-209.71% |
| ROIC |
-5,695.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.50*
(124.46% upside)
Low
6.00
Current: $6.46
High
23.00
Target: 14.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.24 | 0.38 | 0.51 | 0.38 | 0.31 | 0.28 | 0.26 | 0.45 | 0.26 | 0.27 |
| Revenue Growth | -35.34% | -25.14% | 32.63% | 21.82% | 11.65% | 8.07% | -42.44% | 74.78% | -3% | - |
| Gross Profit | 0.24 | -0.22 | -1.31 | -1.35 | -0.32 | 0.26 | 0.26 | 0.45 | 0.26 | 0.27 |
| Operating Income | -16.68 | -17.29 | -25.60 | -40.15 | -25.27 | -14.95 | -10.69 | -4.85 | -2.98 | -5.38 |
| Net Income | -16.41 | -16.46 | -24.91 | -39.20 | -27.47 | -14.33 | -11.81 | -11.57 | -2.24 | -5.45 |
| Shares Outstanding | 5.97 | 2.33 | 0.48 | 0.42 | 0.36 | 0.26 | 0.24 | 0.18 | 0.13 | 0.10 |
| Earnings Per Share | -2.80 | -8.26 | -51.76 | -93.30 | -87.12 | -63.36 | -50.40 | -64.08 | -16.56 | -56.16 |
| Operating Cash Flow | -13.27 | -13.20 | -23.28 | -31.04 | -22.12 | -12.73 | -7.32 | -4.93 | -1.93 | -2.09 |
| Capital Expenditures | -0.07 | 0.02 | -0.10 | -0.82 | -2.23 | -0.30 | -0.65 | -0.27 | - | -0.03 |
| Free Cash Flow | -13.34 | -13.18 | -23.38 | -31.86 | -24.35 | -13.03 | -7.97 | -5.20 | -1.93 | -2.12 |
| Cash & Equivalents | 10.20 | 11.45 | 8.23 | 37.89 | 67.49 | 27.29 | 25.84 | 10.82 | 0.70 | 0.06 |
| Total Debt | 1.73 | - | 1.33 | 16.54 | 16.47 | 14.95 | 0.52 | - | - | 2.34 |
| Net Cash / Debt | 8.47 | 11.45 | 6.89 | 21.36 | 51.02 | 12.34 | 25.32 | 10.82 | 0.70 | -2.28 |
| Assets | 13.09 | 14.17 | 12.28 | 43.95 | 71.45 | 28.90 | 27.16 | 11.67 | 1.04 | 0.51 |
| Liabilities | 5.78 | 4.09 | 5.78 | 24.18 | 22.74 | 20.55 | 6.76 | 9.50 | 5.27 | 5.51 |
| Book Value | 7.31 | 10.08 | 6.51 | 19.77 | 48.70 | 8.35 | 20.39 | 2.17 | -4.23 | -5.00 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cardiff Oncology, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Mark Erlander |
Stock Information
| Ticker Symbol |
CRDF |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRDF |
Description
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.